- Home
- PMVP vs MDXH Comparison
PMVP vs MDXH Comparison
Compare PMVP & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- MDXH
- Stock Information
- Founded
- PMVP 2013
- MDXH 2003
- Country
- PMVP United States
- MDXH Belgium
- Employees
- PMVP N/A
- MDXH N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- MDXH
- Sector
- PMVP Health Care
- MDXH
- Exchange
- PMVP Nasdaq
- MDXH Nasdaq
- Market Cap
- PMVP 85.5M
- MDXH 93.1M
- IPO Year
- PMVP 2020
- MDXH 2021
- Fundamental
- Price
- PMVP $1.37
- MDXH $1.96
- Analyst Decision
- PMVP Strong Buy
- MDXH Strong Buy
- Analyst Count
- PMVP 3
- MDXH 2
- Target Price
- PMVP $5.33
- MDXH $7.00
- AVG Volume (30 Days)
- PMVP 175.1K
- MDXH 145.0K
- Earning Date
- PMVP 02-27-2025
- MDXH 02-26-2025
- Dividend Yield
- PMVP N/A
- MDXH N/A
- EPS Growth
- PMVP N/A
- MDXH N/A
- EPS
- PMVP N/A
- MDXH N/A
- Revenue
- PMVP N/A
- MDXH $84,708,000.00
- Revenue This Year
- PMVP N/A
- MDXH $27.57
- Revenue Next Year
- PMVP N/A
- MDXH $20.09
- P/E Ratio
- PMVP N/A
- MDXH N/A
- Revenue Growth
- PMVP N/A
- MDXH 33.01
- 52 Week Low
- PMVP $1.32
- MDXH $1.55
- 52 Week High
- PMVP $2.26
- MDXH $4.44
- Technical
- Relative Strength Index (RSI)
- PMVP 33.56
- MDXH 38.10
- Support Level
- PMVP $1.32
- MDXH $1.97
- Resistance Level
- PMVP $1.50
- MDXH $2.25
- Average True Range (ATR)
- PMVP 0.07
- MDXH 0.16
- MACD
- PMVP -0.01
- MDXH -0.04
- Stochastic Oscillator
- PMVP 16.61
- MDXH 0.00
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.